Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 12 - 13 tags : Positive save search
Syndax Pharmaceuticals Announces Additional Positive Data Demonstrating Continued Robust Clinical Activity with Durable Responses in Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613
Published: 2021-12-13 (Crawled : 23:00) - biospace.com/
SNDX | $20.82 1.61% 1.59% 850K
|
Health Technology
|
| O: -6.48%
H: 18.59%
C: 10.02%
gment-101 als 613 trial phase 1 positive
SSR Mining Announces Positive Exploration Results at the Amisk Gold Property in Saskatchewan
Published: 2021-12-13 (Crawled : 23:00) - prnewswire.com
SSRM | News | $5.345 3.99% 3.84% 4.4M
|
Non-Energy Minerals
|
| O: -2.6%
H: 1.67%
C: -0.3%
positive results
COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in open-label treatment-resistant depression study
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
CMPS | $8.35 -0.83% -0.84% 370K
|
Health Technology
|
| O: -5.04%
H: 0.0%
C: 0.0%
comp360 treatment positive therapy depression psilocybin
Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
ft596 therapeutics phase 1 positive t-cell
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer
Published: 2021-12-13 (Crawled : 21:00) - globenewswire.com
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 treatment trial lung cancer positive therapy bioscience results cancer phase 3
Allogene Therapeutics Reports Positive Results from Phase 1 UNIVERSAL Study of Single Dose ALLO-715 AlloCAR T™ Cell Therapy in Relapsed/Refractory Multiple Myeloma at the 63rd American Society of Hematology Annual Meeting
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
ALLO | $3.48 0.58% 0.57% 2M
|
Health Technology
|
| O: 1.05%
H: 2.52%
C: -22.56%
allo-715 ema therapeutics positive results phase 1 positive therapy results t-cell
Allogene Therapeutics Reports Positive Phase 1 Data from the ALPHA Trials in Non-Hodgkin’s Lymphoma at the 63rd Annual Meeting of the American Society of Hematology
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
ALLO | $3.48 0.58% 0.57% 2M
|
Health Technology
|
| O: 1.05%
H: 2.52%
C: -22.56%
ema als trials trial therapeutics phase 1 positive
Viracta Therapeutics Announces Final Phase 1b/2 Data Showing Promising and Durable Signal of Efficacy for Nana-val in Relapsed/Refractory Epstein-Barr Virus-Positive Lymphoma in an Oral Presentation at ASH 2021
Published: 2021-12-13 (Crawled : 20:00) - biospace.com/
VIRX | $0.88 -3.19% -3.3% 53K
|
Manufacturing
|
| O: -2.86%
H: 0.0%
C: 0.0%
phase 1b therapeutics presentation phase 1 positive phase 2b
Autolus Therapeutics presents positive obe-cel data at the 63rd ASH Annual Meeting & Exposition
Published: 2021-12-13 (Crawled : 18:00) - biospace.com/
AUTL | $4.51 -6.04% -6.43% 1.4M
|
Health Technology
|
| O: -3.93%
H: 0.0%
C: 0.0%
therapeutics positive cel
Junshi Biosciences and Coherus Announce Positive Interim Overall Survival Results of CHOICE-01
Published: 2021-12-13 (Crawled : 18:00) - biospace.com/
ABBV | News | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 1.07%
H: 0.0%
C: 0.0%
CHRS | $2.06 3.0% 2.91% 2.9M
|
Health Technology
|
| O: -0.83%
H: 0.0%
C: 0.0%
hoice-01 positive bioscience results
GBT Presents Positive Results from Phase 1 Study of GBT021601 in Patients with Sickle Cell Disease and Healthy Volunteers at ASH Annual Meeting and Exposition
Published: 2021-12-13 (Crawled : 15:30) - biospace.com/
GBT | $68.49 0.02% -0.02%
|
Health Technology
|
| O: -12.83%
H: 0.0%
C: 0.0%
gbt0216 health disease positive results phase 1 positive results
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
Published: 2021-12-13 (Crawled : 15:00) - biospace.com/
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
|
| O: -0.1%
H: 0.0%
C: 0.0%
ft516 fda granted therapeutics phase 1 positive therapy t-cell designation
Rocket Pharmaceuticals Presents Positive Clinical Data from Company’s Lentiviral Gene Therapies for Treatment of Fanconi Anemia, LAD-I and PKD at the 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-13 (Crawled : 15:00) - biospace.com/
RCKT M | $22.82 -2.81% -2.89% 960K
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
treatment ema als anemia gene therapies positive gene therapy
Kymera Therapeutics Presents Positive Preclinical Data on Selective STAT3 Degraders for Hematological and Solid Tumor Malignancies at 63rd American Society of Hematology (ASH) Annual Meeting
Published: 2021-12-13 (Crawled : 14:30) - biospace.com/
KYMR | $33.965 -3.29% -3.4% 630K
|
Health Technology
|
| O: -0.57%
H: 0.0%
C: 0.0%
ema therapeutics preclinical positive pre-clinical
Galecto Announces Positive Preliminary Results for Oral Galectin-3 Inhibitor GB1211 in Part 1 of its Phase 1b/2a Liver Cirrhosis Trial
Published: 2021-12-13 (Crawled : 14:00) - biospace.com/
GLTO | $0.72 4.71% 77K
|
Health Technology
|
| O: -5.73%
H: 0.0%
C: 0.0%
gb1211 galectin-3 cirrhosis phase 1b liver trial liver cirrhosis phase 1 positive results phase 2b
Equillium Announces Additional Patient Data at ASH 2021 Demonstrating Continued Positive and Durable Clinical Responses in Acute Graft-Versus-Host Disease Patients Treated with Itolizumab
Published: 2021-12-13 (Crawled : 13:30) - biospace.com/
EQ | $1.63 -5.78% -6.13% 100K
|
Health Technology
|
| O: -0.21%
H: 0.95%
C: -2.11%
disease positive
BELLUS Health Announces Positive Topline Results from its Phase 2b SOOTHE Trial of BLU-5937 for the Treatment of Refractory Chronic Cough
Published: 2021-12-13 (Crawled : 12:30) - biospace.com/
BLU | $14.74 0.03% 0
|
Health Technology
|
| O: 35.91%
H: 0.0%
C: 0.0%
blu-5937 treatment health phase 2 phase 2b trial topline results positive results topline chronic cough
4D pharma announces positive topline results from Part A of Phase I/II trial of MRx-4DP0004 for the treatment of asthma
Published: 2021-12-13 (Crawled : 08:00) - 4dpharmaplc.com
LBPS | $1.65 -0.61%
|
Manufacturing
|
| O: -4.06%
H: 0.0%
C: 0.0%
dp0004 treatment trial topline results positive results topline
Positive Phase 3 Dupixent® (dupilumab) Data in Children 6 Months to 5 Years with Moderate-to-severe Atopic Dermatitis Featured in RAD 2021 Late-breaking Session
Published: 2021-12-13 (Crawled : 08:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 3.01%
H: 0.28%
C: -2.39%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: -1.54%
H: 0.0%
C: 0.0%
dupixent atopic dermatitis dermatitis positive children phase 3
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.